Despite strong private equity interest in drug and device targets, policy changes in the healthcare industry have made the M&A market tricky to navigate. Healthcare has been one of the most active policy focus areas in 2023 and this ongoing policy activity has the potential to impact private equity investors in the industry….
By: Akin Gump Strauss Hauer & Feld LLP
By: Akin Gump Strauss Hauer & Feld LLP
